Anavex Life Sciences Corp. reported a new peer-reviewed publication in the journal Neurobiology of Aging, titled "Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology", featuring the orally available small molecule ANAVEX(R) 3-71 (AF710B). This study ascertains potential disease-modifying properties of ANAVEX(R), 3-71 (AF710 B).

This study ascertains potential Disease-modifying properties of AN AVEX(R)3-71 (AF710B) on Alzheimer's disease (AD) pathology and could be a drug candidate for a once daily oral preventive strategy. ANAVEX(R-71 activates the sigma-1 receptor (SIGMAR1) and the M1 muscarinic receptor (M1R). Data suggests that activation of SIGMAR1 results in the restoration of homeostatic function within the body and is pivotal to restoring neural cell balance and promoting neuroplasticity.

Previous studies of ANAVEX(R-71 have demonstrated its potential to treat Alzheimer's disease (AD)-like pathology at advanced stages of disease in animal models. (.) (4) ANAVEX®? 3-71, an orally available small molecule, has already successfully completed a Phase 1 human clinical trial demonstrating good safety and tolerability signals at all doses studied.

In this publication, transgenic rats that develop AD-like symptoms as they age were treated with ANAVEX(R") 3-71 for 7- months before they developed amyloid plaques, followed by a 4-week washout period. Preventative treatment with ANAVEX(R) 3-71 reduced levels of insoluble and soluble amyloid-beta as well as plaque deposition in the aging cortex and neuro neuroinflammation, areas heavily impacted by AD. This long-lasting effect was also observed in previous animal studies of ANAVEX??

3-71 at advanced stages of the disease. The publication is consistent with previous scientific findings, including with the more advanced drug candidate ANAVEX®? 2-73 (blarcamesine), which successfully completed a Phase 2b/3 study in early Alzheimer's disease, that SIGMAR1 activation acts upstream of multiple contributors to AD and other dementias including but not limited to mitochondrial dysfunction, oxidative stress, impaired autophagy and that amyloid pathology can be reduced by M1R stimulation.

The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX(R). The Michael J. Fox Foundation to develop ANAVEX®?2-73 for the treatment of Parkinson's disease, a condition that is increasingly diagnosed at preclinical stages.